Optimal combination of radiotherapy and endocrine drugs in breast cancer treatment

Cancer/Radiotherapie

Volumn 17, Issue 3, 2013, Pages 208-214

  Zeng, Z J ^a   Li, J H ^b   Zhang, Y J ^b   Zhao, S T ^b  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Breast cancer; Letrozole; Radiotherapy; Tamoxifen

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; LETROZOLE; PROTEIN BAX; PROTEIN BCL 2; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; BAX PROTEIN, HUMAN; NITRILE; TRIAZOLE DERIVATIVE;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CELL VIABILITY; CLINICAL EFFECTIVENESS; CLONOGENIC ASSAY; DNA BINDING; FEMALE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIVITY; TUMOR CELL LINE; WESTERN BLOTTING; BREAST TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOWN REGULATION; DRUG EFFECT; METABOLISM; PATHOLOGY; RADIATION EXPOSURE; UPREGULATION;

ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; AROMATASE INHIBITORS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; FEMALE; HUMANS; NITRILES; PROTO-ONCOGENE PROTEINS C-BCL-2; RADIOTHERAPY DOSAGE; TAMOXIFEN; TRIAZOLES; UP-REGULATION;

EID: 84882997683     PISSN: 12783218     EISSN: 17696658     Source Type: Journal    
DOI: 10.1016/j.canrad.2013.01.014     Document Type: Article

References (21)

1. Legha S.S., Buzdar A.U., Hortobagyi G.N., Wiseman C., Benjamin R.S., Blumenschein G.R. Tamoxifen. Use in treatment of metastatic breast cancer refractory to combination chemotherapy. JAMA 1979, 242:49-52.
2. Azria D., Lemanski C., Zouhair A., Gutowski M., Belkacemi Y., Dubois J.B., et al. [Adjuvant treatment of breast cancer by concomitant hormonotherapy and radiotherapy: state of the art]. Cancer Radiother 2004, 8:188-196.
3. Barnadas A., Gil M., Sanchez-Rovira P., Llombart A., Adrover E., Estevez L.G., et al. Neoadjuvant endocrine therapy for breast cancer: past, present and future. Anticancer Drugs 2008, 19:339-347.
4. Kiang D.T., Kennedy B.J. Tamoxifen (antiestrogen) therapy in advanced breast cancer. Ann Intern Med 1977, 87:687-690.
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
6. Brueggemeier R.W., Hackett J.C., Diaz-Cruz E.S. Aromatase inhibitors in the treatment of breast cancer. Endocr Rev 2005, 26:331-345.
7. Azria D., Larbouret C., Cunat S., Ozsahin M., Gourgou S., Martineau P., et al. Letrozole sensitizes breast cancer cells to ionizing radiation. Breast Cancer Res 2005, 7:R156-R163.
8. Zhang Y., Liu X., Zuo T., Liu Y., Zhang J.H. Tetramethylpyrazine reverses multidrug resistance in breast cancer cells through regulating the expression and function of P-glycoprotein. Med Oncol 2012, 29:534-538.
9. Eckert R.L., Katzenellenbogen B.S. Effects of estrogens and antiestrogens on estrogen receptor dynamics and the induction of progesterone receptor in MCF-7 human breast cancer cells. Cancer Res 1982, 42:139-144.
10. Zhao S.T., Huang X.T., Zhang C., Ke Y. Humanin protects cortical neurons from ischemia and reperfusion injury by the increased activity of superoxide dismutase. Neurochem Res 2012, 37:153-160.
11. Zhao S.T., Chen M., Li S.J., Zhang M.H., Li B.X., Das M., et al. Mitochondrial BNIP3 upregulation precedes endonuclease G translocation in hippocampal neuronal death following oxygen-glucose deprivation. BMC Neurosci 2009, 10:113.
12. Cufer T. Reducing the risk of late recurrence in hormone-responsive breast cancer. Ann Oncol 2007, 18:viii18-viii25.
13. Dixon J.M. Reducing early recurrence with adjuvant aromatase inhibitors: what is the evidence?. Breast 2008, 17:353-360.
14. Ahn P.H., Vu H.T., Lannin D., Obedian E., DiGiovanna M.P., Burtness B., et al. Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. J Clin Oncol 2005, 23:17-23.
15. Cory S., Huang D.C., Adams J.M. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003, 22:8590-8607.
16. Danial N.N., Korsmeyer S.J. Cell death: critical control points. Cell 2004, 116:205-219.
17. Oltvai Z.N., Milliman C.L., Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog Bax, that accelerates programmed cell death. Cell 1993, 74:609-619.
18. Yang E., Zha J., Jockel J., Boise L.H., Thompson C.B., Korsmeyer S.J. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 1995, 80:285-291.
19. Green D.R. Apoptotic pathways: paper wraps stone blunts scissors. Cell 2000, 102:1-4.
20. Borner C. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol Immunol 2003, 39:615-647.
21. Korsmeyer S.J., Shutter J.R., Veis D.J., Merry D.E., Oltvai Z.N. Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol 1993, 4:327-332.